Literature DB >> 1906505

Bacteraemia and fungaemia in adults with cystic fibrosis.

J V Fahy1, M T Keoghan, E J Crummy, M X FitzGerald.   

Abstract

The incidence of bacteraemia and fungaemia was determined in 29 adults with cystic fibrosis (CF) during 50 consecutive admissions to hospital for management of infective exacerbations of pulmonary disease. Blood was drawn for aerobic, anaerobic and fungal cultures from all patients who were febrile on admission or who became febrile during treatment. The population included eight patients who had indwelling venous access systems in situ. The overall incidence of positive blood cultures in febrile patients was 3.5% [95% confidence interval (C.I.), 1-6%]. We recorded one case of Pseudomonas aeruginosa bacteraemia and two cases of Candida albicans fungaemia. The patient with P. aeruginosa bacteraemia died 5 days after isolation of the organism from her blood. The two patients with C. albicans bacteraemia had totally implantable venous access systems (TIVAS) in situ and both recovered following appropriate therapy. These observations suggest that bacteraemia is rare in patients with CF but that there is a significant risk of fungaemia in a susceptible minority. The implications of these findings, as they relate to management of infections and care of indwelling catheters in such patients, are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1906505     DOI: 10.1016/s0163-4453(05)80005-2

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  8 in total

Review 1.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

2.  Higher Plasma Endothelial Markers in Adults with Cystic Fibrosis Compared with Healthy Age-matched Control Subjects.

Authors:  Pavan K Bhatraju; Katie B Hisert; Moira L Aitken; Christopher H Goss; W Conrad Liles; William A Altemeier
Journal:  Ann Am Thorac Soc       Date:  2019-06

Review 3.  Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.

Authors:  N Høiby
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

4.  Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.

Authors:  G Kronborg; A Fomsgaard; C Galanos; M A Freudenberg; N Høiby
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

5.  Totally implantable venous access devices in children with cystic fibrosis: incidence and type of complications.

Authors:  J Deerojanawong; S M Sawyer; A M Fink; K B Stokes; C F Robertson
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

6.  Gallstones containing bacteria are biofilms: bacterial slime production and ability to form pigment solids determines infection severity and bacteremia.

Authors:  Lygia Stewart; J McLeod Griffiss; Gary A Jarvis; Lawrence W Way
Journal:  J Gastrointest Surg       Date:  2007-08       Impact factor: 3.452

7.  Translocated LPS might cause endotoxin tolerance in circulating monocytes of cystic fibrosis patients.

Authors:  Rosa del Campo; Eriel Martínez; Carlos del Fresno; Raquel Alenda; Vanesa Gómez-Piña; Irene Fernández-Ruíz; María Siliceo; Teresa Jurado; Victor Toledano; Francisco Arnalich; Francisco García-Río; Eduardo López-Collazo
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

8.  Bacteraemia and fungaemia in cystic fibrosis patients with febrile pulmonary exacerbation: a prospective observational study.

Authors:  Joerg Grosse-Onnebrink; Florian Stehling; Eva Tschiedel; Margarete Olivier; Uwe Mellies; Rene Schmidt; Jan Buer; Peter-Micheal Rath; Joerg Steinmann
Journal:  BMC Pulm Med       Date:  2017-06-29       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.